Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Matrix Metalloproteinase-2 -1306 C>T Gene Polymorphism is Associated with Reduced Risk of Cancer: a Meta-analysis

  • Haque, Shafiul (Research & Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University) ;
  • Akhter, Naseem (Department of Biosciences, Jamia Millia Islamia (A Central University)) ;
  • Lohani, Mohtashim (Department of Biotechnology, Integral University) ;
  • Ali, Arif (Department of Biosciences, Jamia Millia Islamia (A Central University)) ;
  • Mandal, Raju K. (Research & Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University)
  • Published : 2015.03.04
Download PDF
⟨ Previous Next ⟩

Abstract

Matrix metalloproteinase-2 (MMP2) is an endopeptidase, mainly responsible for degradation of extracellular matrix components, which plays an important role in cancer disease. A single nucleotide polymorphism (SNP) at -1306 disrupts a Sp1-type promoter site. The results from the published studies on the association between MMP2 -1306 C>T polymorphism and cancer risk are contradictory and inconclusive. In the present study, a meta-analysis was therefore performed to evaluate the strength of any association between the MMP2 -1306 C>T polymorphism and risk of cancer. We searched all eligible studies published on association between MMP2 -1306 C>T polymorphism and cancer risk in PubMed (Medline), EMBASE and Google Scholar online web databases until December 2013. Genotype distribution data were collected to calculate the pooled odds ratios (ORs) and 95% confidence intervals (95%CIs) to examine the strength of the association. A total of 8,590 cancer cases and 9,601 controls were included from twenty nine eligible case control studies. Overall pooled analysis suggested significantly reduced risk associated with heterozygous genotype (CT vs CC: OR=0.758, 95%CI=0.637 to 0.902, p=0.002) and dominant model (TT+CT vs CC: OR=0.816, 95%CI=0.678 to 0.982, p=0.032) genetic models. However, allelic (T vs C: OR=0.882, 95%CI=0.738 to 1.055, p=0.169), homozygous (TT vs CC: OR=1.185, 95%CI=0.825 to 1.700, p=0.358) and recessive (TT vs CC+CT: OR=1.268, 95%CI=0.897 to 1.793, p=0.179) models did not show any risk. No evidence of publication bias was detected during the analysis. The results of present meta-analysis suggest that the MMP2 -1306 C>T polymorphism is significantly associated with reduced risk of cancer. However, further studies with consideration of different populations will be required to evaluate this relationship in more detail.

Keywords

References

  1. Aysegül B, Veysi GH, Muzaffer M, et al (2011). Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep, 38, 1469-74. https://doi.org/10.1007/s11033-010-0253-5
  2. Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, et al (2008). Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet, 46, 137-144. https://doi.org/10.1007/s10528-007-9136-4
  3. Bergers G, Brekken R, Mcmahon G, et al (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol, 2, 737-744. https://doi.org/10.1038/35036374
  4. Bjorklund M, Koivunen E (2005). Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta, 1755, 37-69.
  5. Bonomi P (2002). Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol, 29, 78-86. https://doi.org/10.1053/sonc.2002.31528
  6. Burton PR, Hansell AL, Fortier I, et al (2009). Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol, 38, 263-73. https://doi.org/10.1093/ije/dyn147
  7. Chaudhary AK, Pandya S, Mehrotra R, et al (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers, 16, 577-86. https://doi.org/10.3109/1354750X.2011.609602
  8. Cohn LD, Becker BJ (2003). How meta-analysis increases statistical power. Psychol Methods, 3, 243-53.
  9. Cox TR, Erler JT (2011). Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Dis Model Mech, 4, 165-78. https://doi.org/10.1242/dmm.004077
  10. Curran S, Murray GI (1999). Matrix metallproteinases in tumor invasion and metastasis. J Pathol, 189, 300-8. https://doi.org/10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C
  11. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al (2008). Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest, 65, 68-72. https://doi.org/10.1159/000108282
  12. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-188. https://doi.org/10.1016/0197-2456(86)90046-2
  13. Deryugina EI, Quigley JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev, 25, 9-34. https://doi.org/10.1007/s10555-006-7886-9
  14. Dos Reis ST, Pontes J Jr, Villanova FE, et al (2009). Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol, 181, 2320-5. https://doi.org/10.1016/j.juro.2009.01.012
  15. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 7109, 629-34.
  16. Elander N, Soderkvist P, Fransen K (2006). Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res, 26, 791-5.
  17. Guo X, Wang J, Zhang L, et al (2012). Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pac J Cancer Prev, 13, 2853-6 https://doi.org/10.7314/APJCP.2012.13.6.2853
  18. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
  19. Hettiaratchi A, Hawkins NJ, McKenzie G, et al (2007). The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. Br J Cancer, 96, 783-792. https://doi.org/10.1038/sj.bjc.6603630
  20. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 7414, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  21. Hu C, Wang J, Xu Y, et al (2013). Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene, 517, 65-71. https://doi.org/10.1016/j.gene.2012.12.085
  22. Itoh T, Tanioka M, Yoshida H, et al (1998). Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res, 58, 1048-51.
  23. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  24. Kader AK, Shao L, Dinney CP, et al (2006). Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res, 66, 11644-8. https://doi.org/10.1158/0008-5472.CAN-06-1212
  25. Kang SH, Brown DA, Kitajima I, et al (1996). Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promotor. J Biol Chem, 271, 7330-5. https://doi.org/10.1074/jbc.271.13.7330
  26. Kumar R, Malik N, Tungaria A, Kawal P (2011). Matrix metalloproteinase-2 gene polymorphism is not associated with increased glioblastoma multiforme susceptibility: an Indian institutional experience. Neurol India, 59, 236-240. https://doi.org/10.4103/0028-3886.79131
  27. Lebeau A, Muller-Aufdemkamp C, Allmacher C, et al (2004). Cellular protein and mRNA expression patterns of matrix metalloproteinases- 2, -3 and -9 in human breast cancer: correlation with tumour growth. J Mol Histol, 35, 443-455.
  28. Lei H, Hemminki K, Altieri A, et al (2007). Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat, 103, 61-69. https://doi.org/10.1007/s10549-006-9345-2
  29. Li X, Qu L, Zhong Y, et al (2013). Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol, 139, 1433-47. https://doi.org/10.1007/s00432-013-1446-9
  30. Li Y, Sun DL, Duan YN, et al (2010). Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep, 37, 197-205. https://doi.org/10.1007/s11033-009-9593-4
  31. Lichtenstein P, Holm NV, Verkasalo PK, et al (2000). Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85. https://doi.org/10.1056/NEJM200007133430201
  32. Lin SC, Lo SS, Liu CJ, et al (2004). Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med, 33, 405-9. https://doi.org/10.1111/j.1600-0714.2004.00231.x
  33. Liu D, Guo H, Li Y, et al (2012). Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One, 7, 31251. https://doi.org/10.1371/journal.pone.0031251
  34. Mandal RK, Yadav SS, Panda AK (2013). Meta-analysis on the association of nucleotide excision repair gene XPD A751C variant and cancer susceptibility among Indian population. Mol Biol Rep. (Epub ahead of print)
  35. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 4, 719-48.
  36. Martin MD, Matrisian LM (2007). The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev, 26, 717-24. https://doi.org/10.1007/s10555-007-9089-4
  37. Miao X, Yu C, Tan W, et al (2003). A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res, 63, 3987-90.
  38. Nabeshima K, Inoue T, Shimao Y, Sameshima T (2002). Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int, 52, 255-64. https://doi.org/10.1046/j.1440-1827.2002.01343.x
  39. O-Charoenrat P, Khantapura P (2006). The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol, 42, 257-67. https://doi.org/10.1016/j.oraloncology.2005.07.008
  40. Ohtani H, Maeda N, Murawaki Y (2009). Functional polymorphisms in the promoter regions of matrix metalloproteinase-2, -3, -7, -9 and TNF-alpha genes, and the risk of colorectal neoplasms in Japanese. Yonago Acta Medica, 52, 47-56.
  41. Pan MR, Hung WC (2002). Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/ Sp1-mediated transcription. Proc Natl Acad Sci USA, 277, 32775-380.
  42. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60. https://doi.org/10.1038/nrc1476
  43. Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58. https://doi.org/10.1074/jbc.M010242200
  44. Price SJ, Greaves DR, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58. https://doi.org/10.1074/jbc.M010242200
  45. Roehe AV, Frazzon AP, Agnes G, et al (2007). Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat, 102, 123-4. https://doi.org/10.1007/s10549-006-9273-1
  46. Rollin J, Regina S, Vourc'h P, et al (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer, 56, 273-80. https://doi.org/10.1016/j.lungcan.2006.11.021
  47. Saeed HM, Alanazi MS, Parine NR, et al (2013). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the saudi population. Asian Pac J Cancer Prev, 14, 6025-30. https://doi.org/10.7314/APJCP.2013.14.10.6025
  48. Satpute SP, Hazarey VK, Ganvir SM (2012). Estimation of matrix metalloproteinases-2 promoter polymorphism as a risk factor for oral carcinogenesis in Indian population. Scientific reports, 1, 1-4. https://doi.org/10.9734/JSRR/2012/2008
  49. Shalaby MA, Nounou HA, Alanazi MS, et al (2014). Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev, 15, 4989-4994. https://doi.org/10.7314/APJCP.2014.15.12.4989
  50. Srivastava P, Kapoor R, Mittal RD (2013). Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol, 31, 247-54. https://doi.org/10.1016/j.urolonc.2011.01.001
  51. Srivastava P, Lone TA, Kapoor R, Mittal RD (2012). Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res, 43, 117-24. https://doi.org/10.1016/j.arcmed.2012.02.006
  52. Sternlicht MD, Werb Z (1999). Matrix metalloproteinase. In Kreis T and Vale R (eds) guidebook to the extracellular matrix, anchor and adhesion proteins. Oxford University Press, New York, 503-603.
  53. van Kempen LC, de Visser KE, Coussens LM (2006). Inflammation, proteases and cancer. Eur J Cancer, 42, 728-34. https://doi.org/10.1016/j.ejca.2006.01.004
  54. Vihinen P, Kahari VM (2002). Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer, 99, 157-166. https://doi.org/10.1002/ijc.10329
  55. Wagenaar-Miller RA, Gorden L, Matrisian LM (2004). Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev, 23, 119-135. https://doi.org/10.1023/A:1025819214508
  56. Wieczorek E, Reszka E, Jablonowski Z, et al (2013). Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int, 112, 1207-14. https://doi.org/10.1111/bju.12230
  57. Woolf B (1955). On estimating the relation between blood group and disease. Ann Hum Genet, 19, 251-3. https://doi.org/10.1111/j.1469-1809.1955.tb01348.x
  58. Wu R, Li B (1999). A multiplicative-epistatic model for analyzing interspecific differences in outcrossing species. Biometrics, 2, 355-65.
  59. Xu E, Lai M, Lv B, et al (1999). A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun, 324, 999-1003.
  60. Yang L, Li N, Wang S, et al (2014). Lack of association between the matrix metalloproteinase-2 -1306C>T polymorphism and breast cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 15, 4823-7 https://doi.org/10.7314/APJCP.2014.15.12.4823
  61. Yaykasli KO, Kayikci MA, Yamak N, et al (2014). Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci, 44.
  62. Yu C, Pan K, Xing D, et al (2002). Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res, 62, 6430-33.
  63. Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-8. https://doi.org/10.1158/0008-5472.CAN-04-1521
  64. Zhai Y, Qiu W, Dong XJ, et al (2007). Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut, 56, 445-7. https://doi.org/10.1136/gut.2006.112706
  65. Zhou Y, Yu C, Miao X, et al (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis, 25, 399-404.
  66. Zhou Y, Yu C, Miao X, et al (2005). Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis, 26, 1117-21. https://doi.org/10.1093/carcin/bgi057

Cited by

  1. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer vol.37, pp.2, 2016, https://doi.org/10.1007/s13277-015-4013-y
  2. The association between MMP2 −1306 C > T (rs243865) polymorphism and risk of prostate cancer vol.186, pp.1, 2017, https://doi.org/10.1007/s11845-016-1492-9